A First Time in Human, Blinded, Randomised, Placebo-Controlled, Two-Cohort Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Single Oral Escalating Doses of GSK 618334 in Healthy Male Volunteers.
Phase of Trial: Phase I
Latest Information Update: 18 Sep 2017
At a glance
- Drugs GSK 618334 (Primary)
- Indications Impulse control disorders
- Focus Adverse reactions; Pharmacokinetics
- 10 Jun 2017 Biomarkers information updated
- 15 Oct 2008 Actual start date changed from May 2007 to Jun 2007 as reported by Clinicaltrials.gov.
- 18 Jun 2008 Status changed from recruiting to completed as reported by ClinicalTrials.gov.